An interventional study of Surgical strategy based on a software in Epilepsy, sponsored by Assistance Publique Hopitaux De Marseille. Completed at 1 site in France. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille — 6 open to participants now, 7 under way, none of them phase 3. Epilepsy · Assistance Publique Hopitaux De Marseille.
Among the 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille, this one has the largest enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2019, is one of 15 with no phase, and was the 5th registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →6 of the 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18–90 · Healthy volunteers
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 9+
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 16+
Assistance Publique Hopitaux De Marseille · Sites in France
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 12+
By country, each count listing its studies:
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2019.
This study's enrollment of 356 is above the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 60 across the 15 interventional studies, 240 across the 3 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
2 of the studies in Epilepsy by Assistance Publique Hopitaux De Marseille that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06334952Assistance Publique Hopitaux De MarseilleEfficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic | 2026-12-18 |
| NCT05609084Assistance Publique Hopitaux De MarseilleIntensive Preoperative Speech Rehabilitation in Drug-Resistant Temporal Epilepsy | 2027-03-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Every year, thousands of patients worldwide with drug resistant focal epilepsy (DRE) undergo resective brain surgery with the aim of achieving seizure freedom.
Despite technical advances over the last 50 years, the success rate of epilepsy surgery in terms of seizure freedom has not greatly improved, remaining overall at around 50%. Depending on features of individual cases, presurgical evaluation includes a first phase of non-invasive data including video-EEG recordings, magnetoencephalography, structural and functional neuroimaging and neuropsychological evaluation. If these investigations do not allow adequate localization of likely region of seizure organization in the brain (the epileptogenic zone, EZ), then a second invasive phase using intracerebral EEG recording may be necessary (stereoelectroencephalography, SEEG). Interpretation of SEEG remains difficult in many cases, in particular since seizure onset is often characterized by discharges that very rapidly involve several distinct brain regions.
No reliable measuring instrument currently exists to combine the various prognostic factors for a given patient. This leads to great uncertainty on an individual scale in predicting the effects of surgery. The mapping of epileptic networks in patients with DRE is an innovative scientifically-validated and clinically-tested method to significantly improve accuracy of SEEG and presurgical interpretation and guide surgical strategies in patients with DRE. Therefore, the investigators developed the Virtual Epilepsy Patient software. Retrospective study already demonstrated the pertinence of this approach in improving the anatomical mapping of epileptogenic networks. Now, the investigators aim to prospectively demonstrate the role of VEP during presurgical evaluation of DRE patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Surgical strategy based on a software
Surgical strategy décision based on a software
Clinical success, defined as seizure free patient without disabling side effect (clinical judgment) at 12-month follow-up
Number of seizure (Engel I)
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2019 to primary completion in Jun 2023, 47 months.
Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's 47 months is close to that.
Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Dec 2024 → Jun 2023 and completion Dec 2025 → Jun 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille →